J&J EXPANDS CANCER PORTFOLIO WITH $3.05 BILLION HALDA BUY

Johnson & Johnson said on Monday it would buy privately held Halda Therapeutics for $3.05 billion in cash, aiming to expand its presence in treatments targeting solid tumors and prostate cancer.

This marks the medtech conglomerate's second major deal this year, after its $14.6 billion acquisition of neurological drug maker Intra-Cellular Therapies in January, reinforcing its push in higher-growth healthcare segments as it navigates the loss of exclusivity for its blockbuster immune disease treatment Stelara.

Learn More